Genomic alterations as mediators of miRNA dysregulation in ovarian cancer

Genes Chromosomes and Cancer

Volumn 54, Issue 1, 2015, Pages 1-19

  Kan, Casina W S ^a   Howell, Viive M ^a   Hahn, Michael A ^a   Marsh, Deborah J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; MICRORNA; PROTEIN P53; TRANSCRIPTION FACTOR;

BINDING AFFINITY; BINDING SITE; CANCER GRADING; CANCER PROGNOSIS; CARCINOGENESIS; COPY NUMBER VARIATION; DISEASE ASSOCIATION; DISEASE COURSE; DNA DAMAGE; DNA REPAIR; GENE CONTROL; GENE DISRUPTION; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOMIC INSTABILITY; HUMAN; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SEROUS EPITHELIAL OVARIAN CANCER; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GROWTH; GENETICS; METABOLISM; NEOPLASM; OVARY TUMOR; PATHOLOGY;

DNA COPY NUMBER VARIATIONS; DNA REPAIR; GENOMIC INSTABILITY; HUMANS; MICRORNAS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84921974518     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22221     Document Type: Review

References (209)

1. Aghili L, Foo J, Degregori J, De S. 2014. Patterns of somatically acquired amplifications and deletions in apparently normal tissues of ovarian cancer patients. Cell Rep 7:1310-1319.
2. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D, Brenton JD. 2010. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221:49-56.
3. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G. 2012. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30:2654-2663.
4. Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. 2003. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130.
5. Aylon Y, Oren M. 2011. p53: Guardian of ploidy. Mol Oncol 5:315-323.
6. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, Karlan BY. 2000. BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study. Cancer Res 60:5329-5333.
7. Banno K, Yanokura M, Iida M, Adachi M, Nakamura K, Nogami Y, Umene K, Masuda K, Kisu I, Nomura H, Kataoka F, Tominaga E, Aoki D. 2014. Application of MicroRNA in diagnosis and treatment of ovarian cancer. Biomed Res Int 2014: 232817.
8. Bartel DP. 2004. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297.
9. Barton CA, Hacker NF, Clark SJ, O'Brien PM. 2008. DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment. Gynecol Oncol 109:129-139.
10. Bayani J, Kuzmanov U, Saraon P, Fung WA, Soosaipillai A, Squire JA, Diamandis EP. 2013. Copy number and expression alterations of miRNAs in the ovarian cancer cell line OVCAR-3: Impact on kallikrein 6 protein expression. Clin Chem 59:296-305.
11. Belgnaoui SM, Gosden RG, Semmes OJ, Haoudi A. 2006. Human LINE-1 retrotransposon induces DNA damage and apoptosis in cancer cells. Cancer Cell Int 6:13.
12. Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, Mills AA, Elledge SJ, Anderson KV, Hannon GJ. 2003. Dicer is essential for mouse development. Nat Genet 35:215-217.
13. Bhattacharya A, Ziebarth JD, Cui Y. 2014. PolymiRTS Database 3.0: Linking polymorphisms in microRNAs and their target sites with human diseases and biological pathways. Nucleic Acids Res 42:D86-91.
14. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, Eden OB, Varley JM. 2001. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20:4621-4628.
15. Borchert GM, Lanier W, Davidson BL. 2006. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 13:1097-1101.
16. Bowtell DD. 2010. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10:803-808.
17. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, Goodall GJ. 2008. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 68:7846-7854.
18. Brodsky AS, Fischer A, Miller DH, Vang S, Maclaughlan S, Wu HT, Yu J, Steinhoff M, Collins C, Smith PJ, Raphael BJ, Brard L. 2014. Expression profiling of primary and metastatic ovarian tumors reveals differences indicative of aggressive disease. PLoS One 9:e94476.
19. Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, Xu X, Deng CX, Finkel T, Nussenzweig M, Stark JM, Nussenzweig A. 2010. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141:243-254.
20. Calin GA, Sevignani C, Dan Dumitru C, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. 2004. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101:2999-3004.
21. Callinan PA, Batzer MA. 2006. Retrotransposable elements and human disease. Genome Dyn 1:104-115.
22. Cancer Genome Atlas Research Network. 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615.
23. Carroll PE, Okuda M, Horn HF, Biddinger P, Stambrook PJ, Gleich LL, Li YQ, Tarapore P, Fukasawa K. 1999. Centrosome hyperamplification in human cancer: Chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 18:1935-1944.
24. Carthew RW, Sontheimer EJ. 2009. Origins and mechanisms of miRNAs and siRNAs. Cell 136:642-655.
25. Chan KY, Ozcelik H, Cheung AN, Ngan HY, Khoo US. 2002. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res 62:4151-4156.
26. Chang S, Sharan SK. 2012. BRCA1 and MicroRNAs: Emerging networks and potential therapeutic targets. Mol Cell 34:425-432.
27. Chen W, Tang Z, Sun Y, Zhang Y, Wang X, Shen Z, Liu F, Qin X. 2012. miRNA expression profile in primary gastric cancers and paired lymph node metastases indicates that miR-10a plays a role in metastasis from primary gastric cancer to lymph nodes. Exp Ther Med 3:351-356.
28. Chen X, Ba Y, Ma LJ, Cai X, Yin Y, Wang KH, Guo JG, Zhang YJ, Chen JN, Guo X, Li QB, Li XY, Wang WJ, Zhang Y, Wang J, Jiang XY, Xiang Y, Xu C, Zheng PP, Zhang JB, Li RQ, Zhang HJ, Shang XB, Gong T, Ning G, Wang J, Zen K, Zhang JF, Zhang CY. 2008. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997-1006.
29. Ciccia A, Elledge SJ. 2010. The DNA damage response: Making it safe to play with knives. Mol Cell 40:179-204.
30. Collino F, Deregibus MC, Bruno S, Sterpone L, Aghemo G, Viltono L, Tetta C, Camussi G. 2010. Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS One 5:e11803.
31. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. 2007. MicroRNA-34b and microRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 67:8433-8438.
32. Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, Nikitin AY. 2010. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 16:1119-1128.
33. Cortez MA, Calin GA. 2009. MicroRNA identification in plasma and serum: A new tool to diagnose and monitor diseases. Expert Opin Biol Ther 9:703-711.
34. Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, Schultz N, Du Y, Zhang Y, Larsson E, Sheridan R, Xiao W, Spellman PT, Getz G, Wheeler DA, Perou CM, Gibbs RA, Sander C, Hayes DN, Gunaratne PH. 2012. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One 7:e34546.
35. Cubillos-Ruiz JR, Baird JR, Tesone AJ, Rutkowski MR, Scarlett UK, Camposeco-Jacobs AL, Anadon-Arnillas J, Harwood NM, Korc M, Fiering SN, Sempere LF, Conejo-Garcia JR. 2012a. Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res 72:1683-1693.
36. Cubillos-Ruiz JR, Sempere LF, Conejo-Garcia JR. 2012b. Good things come in small packages: Therapeutic anti-tumor immunity induced by microRNA nanoparticles. Oncoimmunology 1:968-970.
37. Dahiya N, Sherman-Baust CA, Wang T-L, Davidson B, Shih I-M, Zhang Y, Wood W, 3rd, Becker KG, Morin PJ. 2008. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 3:e2436.
38. Dallol A, Da Silva NF, Viacava P, Minna JD, Bieche I, Maher ER, Latif F. 2002. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res 62:5874-5880.
39. Darcy KM, Brady WE, Blancato JK, Dickson RB, Hoskins WJ, McGuire WP, Birrer MJ. 2009. Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study. Gynecol Oncol 114:472-479.
40. Davis-Dusenbery BN, Hata A. 2010. Mechanisms of control of microRNA biogenesis. J Biochem 148:381-392.
41. Delfino KR, Rodriguez-Zas SL. 2013. Transcription factor-microRNA-target gene networks associated with ovarian cancer survival and recurrence. PLoS One 8:e58608.
42. Deng CX, Brodie SG. 2000. Roles of BRCA1 and its interacting proteins. Bioessays 22:728-737.
43. Deng S, Calin GA, Croce CM, Coukos G, Zhang L. 2008. Mechanisms of microRNA deregulation in human cancer. Cell Cycle 7:2643-2646.
44. Di Leva G, Croce CM. 2013. The role of microRNAs in the tumorigenesis of ovarian cancer. Front Oncol 3:153.
45. Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P. 2000. Human kallikrein 6 (zyme/protease M/neurosin): A new serum biomarker of ovarian carcinoma. Clin Biochem 33:579-583.
46. Diederichs S, Haber DA. 2006. Sequence variations of microRNAs in human cancer: Alterations in predicted secondary structure do not affect processing. Cancer Res 66:6097-6104.
47. Duursma AM, Kedde M, Schrier M, le Sage C, Agami R. 2008. miR-148 targets human DNMT3b protein coding region. RNA 14:872-877.
48. Ehrlich M. 2002. DNA methylation in cancer: Too much, but also too little. Oncogene 21:5400-5413.
49. Etemadmoghadam D, Weir BA, Au-Yeung G, Alsop K, Mitchell G, George J, Davis S, D'Andrea AD, Simpson K, Hahn WC, Bowtell DD. 2013. Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci USA 110:19489-19494.
50. Finch A, Evans G, Narod SA. 2012. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: Clinical management considerations and recommendations. Womens Health (Lond Engl) 8:543-555.
51. Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AWM, Klijn JGM, Wiemer EAC, Martens JWM. 2008. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA 105:13021-13026.
52. Forman JJ, Legesse-Miller A, Coller HA. 2008. A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence. Proc Natl Acad Sci USA 105:14879-14884.
53. Fukunaga R, Colpan C, Han BW, Zamore PD. 2014. Inorganic phosphate blocks binding of pre-miRNA to Dicer-2 via its PAZ domain. EMBO J 33:371-384.
54. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, Eddington K, McClure M, Frye C, Weaver-Feldhaus J, Ding W, Gholami Z, Soderkvist P, Terry L, Jhanwar S, Berchuck A, Iglehart JD, Marks J, Ballinger DG, Barrett JC, Skolnick MH, Kamb A, Wiseman R. 1994. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266:120-122.
55. Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, Lidereau R, Mikaelian I, Mazoyer S. 2011a. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med 3:279-290.
56. Garcia AI, Cox DG, Barjhoux L, Verny-Pierre C, Barnes D, Antoniou AC, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S. 2011b. The rs2910164:G>C SNP in the MIR146A gene is not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum Mutat 32:1004-1007.
57. Gardiner C. 2007. Family history of gynaecological cancers. Obstet Gynaecol Reprod Med 17:356-361.
58. Geisler JP, Goodheart MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA, Buller RE. 2003. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer 98:2199-2206.
59. George J, Alsop K, Etemadmoghadam D, Hondow H, Mikeska T, Dobrovic A, deFazio A, Smyth GK, Levine DA, Mitchell G, Bowtell DD. 2013. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res 19:3474-3484.
60. Giannakakis A, Sandaltzopoulos R, Greshock J, Liang S, Huang J, Hasegawa K, Li C, O'Brien-Jenkins A, Katsaros D, Weber BL, Simon C, Coukos G, Zhang L. 2008. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 7:255-264.
61. Gong J, Tong Y, Zhang HM, Wang K, Hu T, Shan G, Sun J, Guo AY. 2012. Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis. Hum Mutat 33:254-263.
62. Gorringe KL, Ramakrishna M, Williams LH, Sridhar A, Boyle SE, Bearfoot JL, Li J, Anglesio MS, Campbell IG. 2009. Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis. Genes Chromosomes Cancer 48:931-942.
63. Guil S, Esteller M. 2009. DNA methylomes, histone codes and miRNAs: Tying it all together. Int J Biochem Cell Biol 41:87-95.
64. Guo L, Du Y, Chang S, Zhang K, Wang J. 2014. rSNPBase: A database for curated regulatory SNPs. Nucleic Acids Res 42:D1033-1039.
65. Guo Y, Tian P, Yang C, Liang Z, Li M, Sims M, Lu L, Zhang Z, Li H, Pfeffer LM, Yue J. Silencing the double-stranded RNA binding protein DGCR8 inhibits ovarian cancer cell proliferation, migration, and invasion. Pharm Res 2013:1-10.
66. Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, Rothballer A, Ascano M, Jr., Jungkamp AC, Munschauer M, Ulrich A, Wardle GS, Dewell S, Zavolan M, Tuschl T. 2010. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 141:129-141.
67. Hanel W, Moll UM. 2012. Links between mutant p53 and genomic instability. J Cell Biochem 113:433-439.
68. Haverty PM, Hon LS, Kaminker JS, Chant J, Zhang Z. 2009. High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors. BMC Med Genomics 2:21.
69. He L, Wang HY, Zhang L, Huang L, Li JD, Xiong Y, Zhang MY, Jia WH, Yun JP, Luo RZ, Zheng M. 2014a. Prognostic significance of low DICER expression regulated by miR-130a in cervical cancer. Cell Death Dis 5:e1205.
70. He N, Zheng H, Li P, Zhao Y, Zhang W, Song F, Chen K. 2014b. miR-485-5p binding site SNP rs8752 in HPGD gene is associated with breast cancer risk. PLoS One 9:e102093.
71. Helland A, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ, Pearson RB, Borresen-Dale AL, Huntsman DG, deFazio A, Creighton CJ, Smyth GK, Bowtell DD. 2011. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One 6:e18064.
72. Hermeking H. 2012. MicroRNAs in the p53 network: Micromanagement of tumour suppression. Nat Rev Cancer 12:613-626.
73. Hirasawa A, Saito-Ohara F, Inoue J, Aoki D, Susumu N, Yokoyama T, Nozawa S, Inazawa J, Imoto I. 2003. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 9:1995-2004.
74. Huang RY, Chen GB, Matsumura N, Lai HC, Mori S, Li J, Wong MK, Konishi I, Thiery JP, Goh LK. 2012. Histotype-specific copy-number alterations in ovarian cancer. BMC Med Genomics 5:47.
75. Imam JS, Plyler JR, Bansal H, Prajapati S, Bansal S, Rebeles J, Chen HI, Chang YF, Panneerdoss S, Zoghi B, Buddavarapu KC, Broaddus R, Hornsby P, Tomlinson G, Dome J, Vadlamudi RK, Pertsemlidis A, Chen Y, Rao MK. 2012. Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization. PLoS One 7:e52397.
76. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Menard S, Croce CM. 2007. MicroRNA signatures in human ovarian cancer. Cancer Res 67:8699-8707.
77. Iorio MV, Croce CM. 2012. microRNA involvement in human cancer. Carcinogenesis 33:1126-1133.
78. Kan CW, Hahn MA, Gard GB, Maidens J, Huh JY, Marsh DJ, Howell VM. 2012. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer 12:627.
79. Kim T, Veronese A, Pichiorri F, Lee TJ, Jeon YJ, Volinia S, Pineau P, Marchio A, Palatini J, Suh SS, Alder H, Liu CG, Dejean A, Croce CM. 2011. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 208:875.
80. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM. 2012. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci USA 109:3921-3926.
81. Kim M, Chen X, Chin LJ, Paranjape T, Speed WC, Kidd KK, Zhao H, Weidhaas JB, Slack FJ. 2014. Extensive sequence variation in the 3′ untranslated region of the KRAS gene in lung and ovarian cancer cases. Cell Cycle 13:1030-1040.
82. King MC, Marks JH, Mandell JB. 2003. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643-646.
83. Kobayashi N, Uemura H, Nagahama K, Okudela K, Furuya M, Ino Y, Ito Y, Hirano H, Inayama Y, Aoki I, Nagashima Y, Kubota Y, Ishiguro H. 2012. Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget 3:1455-1471.
84. Kobel M, Huntsman D, Gilks CB. 2008. Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev Mol Med 10:e22.
85. Konkel MK, Batzer MA. 2010. A mobile threat to genome stability: The impact of non-LTR retrotransposons upon the human genome. Semin Cancer Biol 20:211-221.
86. Konstantinopoulos PA, Fountzilas E, Pillay K, Zerbini LF, Libermann TA, Cannistra SA, Spentzos D. 2008. Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. BMC Med Genomics 1:59.
87. Kozomara A, Griffiths-Jones S. 2011. miRBase: Integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 39:D152-157.
88. Krishnan K, Steptoe AL, Martin HC, Wani S, Nones K, Waddell N, Mariasegaram M, Simpson PT, Lakhani SR, Gabrielli B, Vlassov A, Cloonan N, Grimmond SM. 2013. MicroRNA-182-5p targets a network of genes involved in DNA repair. RNA 19:230-242.
89. Kuang Y, Cai J, Li D, Han Q, Cao J, Wang Z. 2013. Repression of dicer is associated with invasive phenotype and chemoresistance in ovarian cancer. Oncol Lett 5:1149-1154.
90. Kumar S, Kumar A, Shah PP, Rai SN, Panguluri SK, Kakar SS. 2011. MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res 4:17.
91. Kunej T, Godnic I, Ferdin J, Horvat S, Dovc P, Calin GA. 2011. Epigenetic regulation of microRNAs in cancer: An integrated review of literature. Mutat Res 717:77-84.
92. LaCroix B, Gamazon ER, Lenkala D, Im HK, Geeleher P, Ziliak D, Cox NJ, Huang RS. 2014. Integrative analyses of genetic variation, epigenetic regulation, and the transcriptome to elucidate the biology of platinum sensitivity. BMC Genomics 15:292.
93. Laddha SV, Nayak S, Paul D, Reddy R, Sharma C, Jha P, Hariharan M, Agrawal A, Chowdhury S, Sarkar C, Mukhopadhyay A. 2013. Genome-wide analysis reveals downregulation of miR-379/miR-656 cluster in human cancers. Biol Direct 8:10.
94. Lagana A, Russo F, Sismeiro C, Giugno R, Pulvirenti A, Ferro A. 2010. Variability in the incidence of miRNAs and genes in fragile sites and the role of repeats and CpG islands in the distribution of genetic material. PLoS One 5:e11166.
95. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. 2001. Identification of novel genes coding for small expressed RNAs. Science 294:853-858.
96. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Orum H. 2010. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327:198-201.
97. Laurent LC. 2008. MicroRNAs in embryonic stem cells and early embryonic development. J Cell Mol Med 12:2181-2188.
98. Le XF, Merchant O, Bast RC, Calin GA. 2010. The roles of microRNAs in the cancer invasion-metastasis cascade. Cancer Microenviron 3:137-147.
99. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN. 2003. The nuclear RNase III Drosha initiates microRNA processing. Nature 425:415-419.
100. Lee I, Ajay SS, Yook JI, Kim HS, Hong SH, Kim NH, Dhanasekaran SM, Chinnaiyan AM, Athey BD. 2009. New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites. Genome Res 19:1175-1183.
101. Lee YM, Lee JY, Ho CC, Hong QS, Yu SL, Tzeng CR, Yang PC, Chen HW. 2011. MicroRNA 34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells. Breast Cancer Res 13:R116.
102. Li C, Li JF, Cai Q, Qiu QQ, Yan M, Liu BY, Zhu ZG. 2012. MiRNA-199a-3p in plasma as a potential diagnostic biomarker for gastric cancer. Ann Surg Oncol 7:7.
103. Li N, Zhou P, Zheng J, Deng J, Wu H, Li W, Li F, Li H, Lu J, Zhou Y, Zhang C. 2014. A polymorphism rs12325489C>T in the lincRNA-ENST00000515084 exon was found to modulate breast cancer risk via GWAS-based association analyses. PLoS One 9:e98251.
104. Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, Gu J, Wu X, Lu K. 2010. Genetic variants in microRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res 70:9765-9776.
105. Lindow M, Kauppinen S. 2012. Discovering the first microRNA-targeted drug. J Cell Biol 199:407-412.
106. Liu CG, Calin GA, Meloon B, Gamliel N, Sevignani C, Ferracin M, Dumitru CD, Shimizu M, Zupo S, Dono M, Alder H, Bullrich F, Negrini M, Croce CM. 2004. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci USA 101:9740-9744.
107. Liu DP, Song H, Xu Y. 2010. A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene 29:949-956.
108. Liu C, Zhang F, Li T, Lu M, Wang L, Yue W, Zhang D. 2012. MirSNP, a database of polymorphisms altering miRNA target sites, identifies miRNA-related SNPs in GWAS SNPs and eQTLs. BMC Genomics 13:661.
109. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebet BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. 2005. MicroRNA expression profiles classify human cancers. Nature 435:834-838.
110. Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H. 2007. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 67:10117-10122.
111. Luense LJ, Carletti MZ, Christenson LK. 2009. Role of Dicer in female fertility. Trends Endocrinol Metab 20:265-272.
112. Lynam-Lennon N, Maher SG, Reynolds JV. 2009. The roles of microRNA in cancer and apoptosis. Biol Rev 84:55-71.
113. Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, Godwin AK. 2009. Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management. Mol Oncol 3:97-137.
114. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J, Weinberg RA. 2010. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12:U247-U252.
115. Marcinkowska M, Szymanski M, Krzyzosiak WJ, Kozlowski P. 2011. Copy number variation of microRNA genes in the human genome. BMC Genomics 12:183.
116. Matsushita M, Takeuchi S, Yang Y, Yoshino N, Tsukasaki K, Taguchi H, Koeffler HP, Seo H. 2005. Methylation of the MLH1 gene in hematological malignancies. Oncol Rep 14:191-194.
117. Mayr D, Kanitz V, Anderegg B, Luthardt B, Engel J, Lohrs U, Amann G, Diebold J. 2006. Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. Am J Clin Pathol 126:101-109.
118. Meng FY, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. 2007. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133:647-658.
119. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. 2008. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359:2641-2650.
120. Micci F, Haugom L, Ahlquist T, Andersen HK, Abeler VM, Davidson B, Trope CG, Lothe RA, Heim S. 2010. Genomic aberrations in borderline ovarian tumors. J Transl Med 8:21.
121. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim B, Rigoutsos I. 2006. A pattern-based method for the identification of microRNA binding sites and their corresponding heteroduplexes. Cell 126:1203-1217.
122. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. 2008. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513-10518.
123. Mogilyansky E, Rigoutsos I. 2013. The miR-17/92 cluster: A comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ 20:1603-1614.
124. Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen K, Weinstock DM, Gorospe M, Harris AL, Helleday T, Chowdhury D. 2011. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 41:210-220.
125. Nagaraja AK, Andreu-Vieyra C, Franco HL, Ma L, Chen R, Han DY, Zhu H, Agno JE, Gunaratne PH, DeMayo FJ, Matzuk MM. 2008. Deletion of Dicer in somatic cells of the female reproductive tract causes sterility. Mol Endocrinol 22:2336-2352.
126. Nakamoto M, Jin P, O'Donnell WT, Warren ST. 2005. Physiological identification of human transcripts translationally regulated by a specific microRNA. Hum Mol Genet 14:3813-3821.
127. Nam EJ, Yoon HJ, Kim SW, Kim HG, Kim YT, Kim JH, Kim JW, Kim SH. 2008. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14:2690-2695.
128. Nichols KE, Malkin D, Garber JE, Fraumeni JF, Jr., Li FP. 2001. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomark Prev 10:83-87.
129. Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C, Fu C, Lindow M, Stenvang J, Straarup EM, Hansen HF, Koch T, Pappin D, Hannon GJ, Kauppinen S. 2011. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43:371-378.
130. Oikawa T, Okuda M, Ma Z, Goorha R, Tsujimoto H, Inokuma H, Fukasawa K. 2005. Transcriptional control of BubR1 by p53 and suppression of centrosome amplification by BubR1. Mol Cell Biol 25:4046-4061.
131. Olive V, Jiang I, He L. 2010. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 42:1348-1354.
132. Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H. 1998. BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci USA 95:2302-2306.
133. Paige AJW, Brown R. 2008. Pharmaco(epi)genomics in ovarian cancer. Pharmacogenomics 9:1825-1834.
134. Permuth-Wey J, Kim D, Tsai YY, Lin HY, Chen YA, Barnholtz-Sloan J, Birrer MJ, Bloom G, Chanock SJ, Chen Z, Cramer DW, Cunningham JM, Dagne G, Ebbert-Syfrett J, Fenstermacher D, Fridley BL, Garcia-Closas M, Gayther SA, Ge W, Gentry-Maharaj A, Gonzalez-Bosquet J, Goode EL, Iversen E, Jim H, Kong W, McLaughlin J, Menon U, Monteiro AN, Narod SA, Pharoah PD, Phelan CM, Qu X, Ramus SJ, Risch H, Schildkraut JM, Song H, Stockwell H, Sutphen R, Terry KL, Tyrer J, Vierkant RA, Wentzensen N, Lancaster JM, Cheng JQ, Sellers TA. 2011. LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res 71:3896-3903.
135. Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Chen YA, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Lee N, Larson MC, Aben KK, Anton-Culver H, Antonenkova N, Antoniou AC, Armasu SM, Bacot F, Baglietto L, Bandera EV, Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Cai Q, Campbell I, Chang-Claude J, Chanock S, Chenevix-Trench G, Cheng JQ, Cicek MS, Coetzee GA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dork T, du Bois A, Durst M, Easton DF, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher DA, Flanagan JM, Garcia-Closas M, Gentry-Maharaj A, Giles GG, Glasspool RM, Gonzalez-Bosquet J, Goodman MT, Gore M, Gorski B, Gronwald J, Hall P, Halle MK, Harter P, Heitz F, Hillemanns P, Hoatlin M, Hogdall CK, Hogdall E, Hosono S, Jakubowska A, Jensen A, Jim H, Kalli KR, Karlan BY, Kaye SB, Kelemen LE, Kiemeney LA, Kikkawa F, Konecny GE, Krakstad C, Kjaer SK, Kupryjanczyk J, Lambrechts D, Lambrechts S, Lancaster JM, Le ND, Leminen A, Levine DA, Liang D, Lim BK, Lin J, Lissowska J, Lu KH, Lubinski J, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson SH, Orlow I, Paul J, Pearce CL, Pejovic T, Pelttari LM, Pike MC, Poole EM, Raska P, Renner SP, Risch HA, Rodriguez-Rodriguez L, Rossing MA, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shridhar V, Shu XO, Shvetsov YB, Sieh W, Song H, Southey MC, Spiewankiewicz B, Stram D, Sutphen R, Teo SH, Terry KL, Tessier DC, Thompson PJ, Tworoger SS, van Altena AM, Vergote I, Vierkant RA, Vincent D, Vitonis AF, Wang-Gohrke S, Palmieri Weber R, Wentzensen N, Whittemore AS, Wik E, Wilkens LR, Winterhoff B, Woo YL, Wu AH, Xiang YB, Yang HP, Zheng W, Ziogas A, Zulkifli F, Phelan CM, Iversen E, Schildkraut JM, Berchuck A, Fridley BL, Goode EL, Pharoah PD, Monteiro AN, Sellers TA, Gayther SA. 2013. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun 4:1627.
136. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH. 2001. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195:451-456.
137. Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, Hastings ML, Duelli DM. 2010. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 5:e13515.
138. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. 2000. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60:6039-6044.
139. Pollock A, Bian S, Zhang C, Chen Z, Sun T. 2014. Growth of the developing cerebral cortex is controlled by microRNA-7 through the p53 pathway. Cell Rep 7:1184-96.
140. Pongsavee M, Yamkamon V, Dakeng S, O-charoenrat P, Smith DR, Saunders GF, Patmasiriwat P. 2009. The BRCA1 3′-UTR: 5711+421T/T_5711+1286T/T genotype is a possible breast and ovarian cancer risk factor. Genet Test Mol Biomarkers 13:307-317.
141. Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, Spellman PT, Wang Y, Miller DM, Horsman D, Faham M, Gilks CB, Gray J, Huntsman DG. 2008. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8:17.
142. Rafii A, Touboul C, Al Thani H, Suhre K, Malek JA. 2014. Where cancer genomics should go next: A clinician's perspective. Hum Mol Genet 23:R69-R75.
143. Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PD, Sinilnikova OM, Beesley J, Chen X, McGuffog L, Healey S, Couch FJ, Wang X, Fredericksen Z, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Roversi G, Barile M, Viel A, Allavena A, Ottini L, Papi L, Gismondi V, Capra F, Radice P, Greene MH, Mai PL, Andrulis IL, Glendon G, Ozcelik H, Thomassen M, Gerdes AM, Kruse TA, Cruger D, Jensen UB, Caligo MA, Olsson H, Kristoffersson U, Lindblom A, Arver B, Karlsson P, Stenmark Askmalm M, Borg A, Neuhausen SL, Ding YC, Nathanson KL, Domchek SM, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Gronwald J, Gorski B, Cybulski C, Debniak T, Osorio A, Duran M, Tejada MI, Benitez J, Hamann U, Rookus MA, Verhoef S, Tilanus-Linthorst MA, Vreeswijk MP, Bodmer D, Ausems MG, van Os TA, Asperen CJ, Blok MJ, Meijers-Heijboer HE, Peock S, Cook M, Oliver C, Frost D, Dunning AM, Evans DG, Eeles R, Pichert G, Cole T, Hodgson S, Brewer C, Morrison PJ, Porteous M, Kennedy MJ, Rogers MT, Side LE, Donaldson A, Gregory H, Godwin A, Stoppa-Lyonnet D, Moncoutier V, Castera L, Mazoyer S, Barjhoux L, Bonadona V, Leroux D, Faivre L, Lidereau R, Nogues C, Bignon YJ, Prieur F, Collonge-Rame MA, Venat-Bouvet L, Fert-Ferrer S, Miron A, Buys SS, Hopper JL, Daly MB, John EM, Terry MB, Goldgar D, Hansen T, Jonson L, Ejlertsen B, Agnarsson BA, Offit K, Kirchhoff T, Vijai J, Dutra-Clarke AV, Przybylo JA, Montagna M, Casella C, Imyanitov EN, Janavicius R, Blanco I, Lazaro C, Moysich KB, Karlan BY, Gross J, Beattie MS, Schmutzler R, Wappenschmidt B, Meindl A, Ruehl I, Fiebig B, Sutter C, Arnold N, Deissler H, Varon-Mateeva R, Kast K, Niederacher D, Gadzicki D, Caldes T, de la Hoya M, Nevanlinna H, Aittomaki K, Simard J, Soucy P, Spurdle AB, Holland H, Chenevix-Trench G, Easton DF, Antoniou AC. 2011. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 103:105-116.
144. Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. 2010. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res 70:6509-6515.
145. Rebbeck TR, Kauff ND, Domchek SM. 2009. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80-87.
146. Redis RS, Calin S, Yang Y, You MJ, Calin GA. 2012. Cell-to-cell miRNA transfer: From body homeostasis to therapy. Pharmacol Ther 136:169-174.
147. Rigoutsos I. 2009. New tricks for animal microRNAS: Targeting of amino acid coding regions at conserved and nonconserved sites. Cancer Res 69:3245-3248.
148. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. 2004. Identification of mammalian microRNA host genes and transcription units. Genome Res 14:1902-1910.
149. Rohozinski J, Edwards CL, Anderson ML. 2012. Does expression of the retrogene UTP14c in the ovary pre-dispose women to ovarian cancer? Med Hypotheses 78:446-449.
150. Ross JP, Rand KN, Molloy PL. 2010. Hypomethylation of repeated DNA sequences in cancer. Epigenomics 2:245-269.
151. Ryland GL, Bearfoot JL, Doyle MA, Boyle SE, Choong DY, Rowley SM, Tothill RW, Gorringe KL, Campbell IG. 2012. MicroRNA genes and their target 3′-untranslated regions are infrequently somatically mutated in ovarian cancers. PLoS One 7:e35805.
152. Sabarinathan R, Tafer H, Seemann SE, Hofacker IL, Stadler PF, Gorodkin J. 2013. RNAsnp: Efficient detection of local RNA secondary structure changes induced by SNPs. Hum Mutat 34:546-556.
153. Salvador S, Rempel A, Soslow RA, Gilks B, Huntsman D, Miller D. 2008. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol 110:408-417.
154. Santaris Pharma A/S. Santaris Pharma A/S Phase 2a data of miravirsen shows dose-dependent, prolonged viral reduction of 2-3 logs HCV RNA after four-week treatment in Hepatitis C patients. 2011. Available at http://www.santaris.com/sites/default/files/SantarisPharmaAASLDPhase2dataFINALpressrelease11.5.11.pdf. Accessed on September 24, 2014.
155. Schickel R, Boyerinas B, Park SM, Peter ME. 2008. MicroRNAs: Key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 27:5959-5974.
156. Schlegel BP, Green VJ, Ladias JA, Parvin JD. 2000. BRCA1 interaction with RNA polymerase II reveals a role for hRPB2 and hRPB10alpha in activated transcription. Proc Natl Acad Sci USA 97:3148-3153.
157. Scully R. 2001. Interactions between BRCA proteins and DNA structure. Exp Cell Res 264:67-73.
158. Shalgi R, Pilpel Y, Oren M. 2010. Repression of transposable-elements-A microRNA anti-cancer defense mechanism? Trends Genet 26:253-259.
159. Shen J, Ambrosone CB, DiCioccio RA, Odunsi K, Lele SB, Zhao H. 2008. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis 29:1963-1966.
160. Shen J, DiCioccio R, Odunsi K, Lele SB, Zhao H. 2010. Novel genetic variants in miR-191 gene and familial ovarian cancer. BMC Cancer 10:47.
161. Shen J, Wang D, Gregory SR, Medico L, Hu Q, Yan L, Odunsi K, Lele SB, Ambrosone CB, Liu S, Zhao H. 2012. Evaluation of microRNA expression profiles and their associations with risk alleles in lymphoblastoid cell lines of familial ovarian cancer. Carcinogenesis 33:604-612.
162. Shukla V, Coumoul X, Lahusen T, Wang RH, Xu X, Vassilopoulos A, Xiao C, Lee MH, Man YG, Ouchi M, Ouchi T, Deng CX. 2010. BRCA1 affects global DNA methylation through regulation of DNMT1. Cell Res 20:1201-1215.
163. Sibley CR, Seow Y, Saayman S, Dijkstra KK, El Andaloussi S, Weinberg MS, Wood MJ. 2012. The biogenesis and characterization of mammalian microRNAs of mirtron origin. Nucleic Acids Res 40:438-448.
164. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R, Dork T, Goode EL, Goodman MT, Schildkraut JM, Sellers T, Baglietto L, Beckmann MW, Beesley J, Blaakaer J, Carney ME, Chanock S, Chen Z, Cunningham JM, Dicks E, Doherty JA, Durst M, Ekici AB, Fenstermacher D, Fridley BL, Giles G, Gore ME, De Vivo I, Hillemanns P, Hogdall C, Hogdall E, Iversen ES, Jacobs IJ, Jakubowska A, Li D, Lissowska J, Lubinski J, Lurie G, McGuire V, McLaughlin J, Medrek K, Moorman PG, Moysich K, Narod S, Phelan C, Pye C, Risch H, Runnebaum IB, Severi G, Southey M, Stram DO, Thiel FC, Terry KL, Tsai YY, Tworoger SS, Van Den Berg DJ, Vierkant RA, Wang-Gohrke S, Webb PM, Wilkens LR, Wu AH, Yang H, Brewster W, Ziogas A, Houlston R, Tomlinson I, Whittemore AS, Rossing MA, Ponder BA, Pearce CL, Ness RB, Menon U, Kjaer SK, Gronwald J, Garcia-Closas M, Fasching PA, Easton DF, Chenevix-Trench G, Berchuck A, Pharoah PD, Gayther SA. 2009. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 41:996-1000.
165. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. 2008. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 111:478-486.
166. Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, Zagatti B, Fabbri M, Veronese A, Liu X, Davuluri R, Croce CM, Mills G, Negrini M, Calin GA. 2010. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ 17:246-254.
167. Starkey Lewis PJ, Merz M, Couttet P, Grenet O, Dear J, Antoine DJ, Goldring C, Park BK, Moggs JG. 2012. Serum microRNA biomarkers for drug-induced liver injury. Clin Pharmacol Ther 92:291-293.
168. Sung CO, Song IH, Sohn I. 2013. A distinctive ovarian cancer molecular subgroup characterized by poor prognosis and somatic focal copy number amplifications at chromosome 19. Gynecol Oncol 132:343-50.
169. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. 2009. Modulation of microRNA processing by p53. Nature 460:529-533.
170. Swart M, Dandara C. 2014. Genetic variation in the 3′-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: Potential effects on regulation by microRNA and pharmacogenomics relevance. Front Genet 5:167.
171. Tarapore P, Fukasawa K. 2002. Loss of p53 and centrosome hyperamplification. Oncogene 21:6234-6240.
172. Tavassoli FA, Devilee P. 2003. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press.
173. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I. 2008. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 455:1124-1128.
174. Taylor DD, Gercel-Taylor C. 2005. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer 92:305-311.
175. Teugels E, De Brakeleer S, Goelen G, Lissens W, Sermijn E, De Greve J. 2005. De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes. Hum Mutat 26:284.
176. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv L, Gertig D, deFazio A, Bowtel DDL. 2008. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14:5198-5208.
177. Tran N, Hutvagner G. 2013. Biogenesis and the regulation of the maturation of miRNAs. Essays Biochem 54:17-28.
178. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. 2011. Characterization of extracellular circulating microRNA. Nucleic Acids Res 39:7223-7233.
179. Turchinovich A, Weiz L, Burwinkel B. 2012. Extracellular miRNAs: The mystery of their origin and function. Trends Biochem Sci 37:460-465.
180. Urzua U, Frankenberger C, Gangi L, Mayer S, Burkett S, Munroe DJ. 2005. Microarray comparative genomic hybridization profile of a murine model for epithelial ovarian cancer reveals genomic imbalances resembling human ovarian carcinomas. Tumor Biol 26:236-244.
181. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. 2007. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654-659.
182. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. 2006. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103:2257-2261.
183. von Gise A, Pu WT. 2012. Endocardial and epicardial epithelial to mesenchymal transitions in heart development and disease. Circ Res 110:1628-1645.
184. Waldman SA, Terzic A. 2009. A study of microRNAs in silico and in vivo: Diagnostic and therapeutic applications in cancer. FEBS J 276:2157-2164.
185. Wang Q, Zhang H, Kajino K, Greene MI. 1998. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene 17:1939-1948.
186. Wang Y, Hu X, Greshock J, Shen L, Yang X, Shao Z, Liang S, Tanyi JL, Sood AK, Zhang L. 2012. Genomic DNA copy-number alterations of the let-7 family in human cancers. PLoS One 7:e44399.
187. Wang PY, Gao ZH, Jiang ZH, Li XX, Jiang BF, Xie SY. 2013. The associations of single nucleotide polymorphisms in miR-146a, miR-196a and miR-499 with breast cancer susceptibility. PLoS One 8:e70656.
188. Wang L, Zhu MJ, Ren AM, Wu HF, Han WM, Tan RY, Tu RQ. 2014. A ten-microRNA signature identified from a genome-wide microrna expression profiling in human epithelial ovarian cancer. PLoS One 9:e96472.
189. Warner DR, Mukhopadhyay P, Brock G, Webb CL, Michele Pisano M, Greene RM. 2014. MicroRNA expression profiling of the developing murine upper lip. Dev Growth Differ 56:434-447.
190. Watanabe T, Imoto I, Kosugi Y, Ishiwata I, Inoue S, Takayama M, Sato A, Inazawa J. 2001. A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization. Gynecol Oncol 81:172-177.
191. Watts GS, Futscher BW, Holtan N, Degeest K, Domann FE, Rose SL. 2008. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics 1:47.
192. Weber RG, Bridger JM, Benner A, Weisenberger D, Ehemann V, Reifenberger G, Lichter P. 1998. Centrosome amplification as a possible mechanism for numerical chromosome aberrations in cerebral primitive neuroectodermal tumors with TP53 mutations. Cytogenet Cell Genet 83:266-269.
193. Weber B, Stresemann C, Brueckner B, Lyko F. 2007. Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle 6:1001-1005.
194. Welcsh PL, King MC. 2001. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 10:705-713.
195. Wojnarowicz PM, Oros KK, Quinn MC, Arcand SL, Gambaro K, Madore J, Birch AH, de Ladurantaye M, Rahimi K, Provencher DM, Mes-Masson AM, Greenwood CM, Tonin PN. 2012. The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome. PLoS One 7:e45484.
196. Wong KY, Yu L, Chim CS. 2011. DNA methylation of tumor suppressor miRNA genes: A lesson from the miR-34 family. Epigenomics 3:83-92.
197. Wright GW, Simon RM. 2003. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 19:2448-2455.
198. Wrzeszczynski KO, Varadan V, Byrnes J, Lum E, Kamalakaran S, Levine DA, Dimitrova N, Zhang MQ, Lucito R. 2011. Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer. PLoS One 6:e28503.
199. Wu M, Jolicoeur N, Li Z, Zhang L, Fortin Y, L′Abbe D, Yu Z, Shen SH. 2008. Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis 29:1710-1716.
200. Xiang J, Wu J. 2010. Feud or Friend? The role of the miR-17-92 cluster in tumorigenesis. Curr Genomics 11:129-135.
201. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ. 2008a. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68:425-433.
202. Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, Liang S, Leminen A, Deng S, Smith L, Johnstone CN, Chen XM, Liu CG, Huang Q, Katsaros D, Calin GA, Weber BL, Butzow R, Croce CM, Coukos G, Zhang L. 2008b. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 68:10307-10314.
203. Yuan Z, Sun X, Liu H, Xie J. 2011. MicroRNA genes derived from repetitive elements and expanded by segmental duplication events in mammalian genomes. PLoS One 6:e17666.
204. Zeimet AG, Fiegl H, Goebel G, Kopp F, Allasia C, Reimer D, Steppan I, Mueller-Holzner E, Ehrlich M, Marth C. 2011. DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer. Gynecol Oncol 121:24-31.
205. Zen K, Zhang CY. 2012. Circulating microRNAs: A novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 32:326-348.
206. Zhang BH, Pan XP, Cox SB, Cobb GP, Anderson TA. 2006a. Evidence that miRNAs are different from other RNAs. Cell Mol Life Sci 63:246-254.
207. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward MR, Yao G, Medina A, O'Brien-Jenkins A, Katsaros D, Hatzigeorgiou A, Gimotty PA, Weber BL, Coukos G. 2006b. MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 103:9136-9141.
208. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, Johnstone CN, Megraw MS, Adams S, Lassus H, Huang J, Kaur S, Liang S, Sethupathy P, Leminen A, Simossis VA, Sandaltzopoulos R, Naomoto Y, Katsaros D, Gimotty PA, DeMichele A, Huang Q, Butzow R, Rustgi AK, Weber BL, Birrer MJ, Hatzigeorgiou AG, Croce CM, Coukos G. 2008. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 105:7004-7009.
209. Zhou X, Duan X, Qian J, Li F. 2009. Abundant conserved microRNA target sites in the 5′-untranslated region and coding sequence. Genetica 137:159-164.